IP Library Granted Patent US 10,294,471
Granted Patent B2
US 10,294,471 · App. 15/414,376 · Granted May 21, 2019

Method of isolating aptamers for minimal residual disease detection

Inventors: Qiao Lin (New York, NY); Milan N. Stojanovic (Ridgewood, NJ); Timothy R. Olsen (New York, NY); Tilla S. Worgall (New York, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C12N15/10C12N15/115C12N2310/16C12N2320/11C12N2330/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,294,471
App. No.
15/414,376
Granted
May 21, 2019
Kind
B2
Abstract

A method for selecting and isolating aptamers that target M-Ig proteins with a microdevice including at least a first selection chamber is provided. The method includes preparing a first sample of M-Ig proteins from a serum; placing the M-Ig proteins in the first selection chamber; introducing a first group of oligomers including at least an M-Ig targeting oligomer into the first selection chamber, whereby the M-Ig targeting oligomer binds to the first sample of M-Ig proteins. The method further includes removing unbound oligomers of the first sample from the first selection chamber to isolate the M-Ig targeting oligomer.

Claims (24)

1. A method for selecting and isolating aptamers that target M-Ig proteins, comprising:

a) providing a microdevice to select and isolate M-Ig targeting oligomers comprising:

a first selection chamber for positive selection,

a second selection chamber for counter-selection, wherein the first selection chamber is connected to the second chamber via a first channel,

a third selection chamber for negative selection, wherein the second selection chamber is connected to the third selection chamber via a second channel, and

an amplification chamber, wherein the amplification chamber is connected to at least one of the first chamber, second chamber, and third chamber via a third channel, wherein the first, second, and third channels are configured to hydrodynamically and/or electrokinetically transfer a solution;

b) obtaining a first sample of M-Ig proteins from a serum;

c) placing the first sample of M-Ig proteins in the first selection chamber;

d) placing a second sample of M-Ig or polyclonal immunoglobulin proteins having a heavy and light chain substantially similar to the first sample of M-Ig proteins in the second selection chamber;

e) placing beads without a molecular coating in the third selection chamber;

f) introducing a first group of oligomers including at least an M-Ig targeting oligomer into the first selection chamber, whereby the M-Ig targeting oligomer binds to the first sample of M-Ig proteins;

g) removing unbound oligomers from the first selection chamber to isolate the M-Ig targeting oligomer;

h) transferring the M-Ig targeting oligomer to the second selection chamber, whereby an unbound oligomer is counter-selected;

i) transferring the counter-selected unbound oligomer to the third selection chamber, whereby a subsequent unbound oligomer is negatively selected from the counter-selected unbound oligomer;

j) transferring the subsequent unbound M-Ig targeting oligomer to the amplification chamber through the second channel by a pressure-driven or electrokinetic-driven flow; and

k) amplifying the M-Ig targeting oligomer in the amplification chamber by polymerase chain reaction.

2. The method of claim 1 , wherein the obtaining of the first sample of M-Ig proteins comprises gel electrophoresis; and isoelectric focusing.

3. The method of claim 1 , further comprising purifying the M-Ig proteins using affinity purification after the obtaining of the first sample of M-Ig proteins.

4. The method of claim 3 , wherein the affinity purification comprises using a immunoglobulin specific recombinant bacterial binding protein.

5. The method of claim 1 , wherein the first selection chamber comprises microbeads functionalized with a target M-Ig protein, wherein the method further comprises immobilizing the first sample of M-Ig proteins on the microbeads in the first selection chamber.

6. The method of claim 5 , wherein the microbeads comprise N-hydroxysuccinimde (NHS) groups functionalized magnetic beads to immobilize the M-Ig proteins.

7. The method of claim 1 , wherein the amplification chamber comprises primer-functionalized magnetic beads configured to capture the M-Ig targeting oligomer.

8. The method of claim 1 , further comprising forming the first selection chamber, the second selection chamber, the third selection chamber, and the amplification chamber on a microchip.

9. The method of claim 8 , further comprising hydrodynamically or electrokinetically transferring the M-Ig targeting oligomer from the amplification chamber to the first selection chamber.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: LIN, QIAO; STOJANOVIC, MILAN N.; OLSEN, TIMOTHY R.; WORGALL, TILLA S.
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 044873/0229 →
CONFIRMATORY LICENSE Recorded Aug 16, 2017
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043570/0439 →
Continuity (3)
Continuation PCTUS2015043824 · Aug 5, 2015
Provisional Application 62033574 · Aug 5, 2014
Related Publication 20170130218A1 · May 11, 2017